MedTrace Logo

Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

NCT03692663 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-08-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of TABP EIC in patients with Metastatic castration-resistant prostate cancer.

Conditions

Interventions

DRUG

TABP EIC

A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.

BIOLOGICAL

Cyclophosphamide

Cyclophosphamide will be iv administered with 250 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.

BIOLOGICAL

fludarabine

Fludarabine will be iv administered with 25 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.

Sponsors & Collaborators

  • Tianjin People's Hospital

    collaborator OTHER

  • Allife Medical Science and Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Huaqing Wang, Doctor · Oncology of Tianjin people's hospital, 190 Jianyuan Road, Hongqiao District, Tianjin

  • Jian Li, Doctor · Urinary surgeryof Tianjin people's hospital, 190 Jianyuan Road, Hongqiao District, Tianjin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2023-06-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03692663 on ClinicalTrials.gov